- Home
- ESPR vs ABSI Comparison
ESPR vs ABSI Comparison
Compare ESPR & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- ABSI
- Stock Information
- Founded
- ESPR 2008
- ABSI 2011
- Country
- ESPR United States
- ABSI United States
- Employees
- ESPR N/A
- ABSI N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- ABSI Health Care
- Exchange
- ESPR Nasdaq
- ABSI Nasdaq
- Market Cap
- ESPR 202.2M
- ABSI 338.0M
- IPO Year
- ESPR 2013
- ABSI 2021
- Fundamental
- Price
- ESPR $1.17
- ABSI $2.76
- Analyst Decision
- ESPR Buy
- ABSI Strong Buy
- Analyst Count
- ESPR 6
- ABSI 5
- Target Price
- ESPR $6.50
- ABSI $8.40
- AVG Volume (30 Days)
- ESPR 3.2M
- ABSI 3.9M
- Earning Date
- ESPR 08-11-2025
- ABSI 08-13-2025
- Dividend Yield
- ESPR N/A
- ABSI N/A
- EPS Growth
- ESPR N/A
- ABSI N/A
- EPS
- ESPR N/A
- ABSI N/A
- Revenue
- ESPR $259,574,000.00
- ABSI $4,815,000.00
- Revenue This Year
- ESPR $4.07
- ABSI $81.76
- Revenue Next Year
- ESPR N/A
- ABSI $287.79
- P/E Ratio
- ESPR N/A
- ABSI N/A
- Revenue Growth
- ESPR 12.99
- ABSI N/A
- 52 Week Low
- ESPR $0.69
- ABSI $2.01
- 52 Week High
- ESPR $3.94
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- ESPR 61.04
- ABSI 47.40
- Support Level
- ESPR $0.95
- ABSI $2.49
- Resistance Level
- ESPR $1.06
- ABSI $2.86
- Average True Range (ATR)
- ESPR 0.08
- ABSI 0.16
- MACD
- ESPR -0.00
- ABSI -0.01
- Stochastic Oscillator
- ESPR 81.48
- ABSI 42.78
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.